Needs Assessment for a Dissemination Program of the CAG Guidelines in Ulcerative Colitis

Section One:

Please answer the following questions about your current treatment strategies for ambulatory, moderate to severe UC patients.

Question Title

* 1. Do you believe that complete remission, defined as both symptomatic and endoscopic remission, is an achievable treatment target in ulcerative colitis?

Never

Rarely

Sometimes

Frequently

Always

Please comment:

Question Title

* 2. Do you find oral corticosteroids to be effective in: (Please choose one)

Inducing complete remission

Maintaining complete remission

Both of the above

None of the above

If you answered a, b or c please specify as never, rarely, sometimes, frequently, or always

Question Title

* 3. How long do you typically or usually wait before assessing response to corticosteroids in patients with ulcerative colitis?

2 weeks

4 weeks

6 weeks

8 weeks

10 weeks

12 weeks

Other (please specify)

Question Title

* 4. Do you consider thiopurine monotherapy to be a reasonable option for induction of remission?

Never

Rarely

Sometimes

Frequently

Always

Other (please specify)

Question Title

* 5. Do you consider thiopurine monotherapy to be a reasonable option to maintain complete corticosteroid remission in selected patients who have achieved symptomatic remission on oral corticosteroids?

Never

Rarely

Sometimes

Frequently

Always

Other (please specify)

Question Title

* 6. In your patients starting on anti-TNF therapy do you most often: (Please choose one)

Combine the biologic with thiopurine

Combine the biologic with methotrexate

Use the biologic as monotherapy

Question Title

* 7. In patients with ulcerative colitis on anti-TNF induction therapy, when do you usually evaluate for lack of symptomatic response to determine the need to modify therapy. (Please choose one)

2 months

3 months

6 months

9 months

12 months

Other (please specify)

Question Title

* 8. What is the next step in your treatment approach in patients with ulcerative colitis who have a suboptimal response to anti-TNF induction therapy. (Please specify)